Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tetsuya Takao

Showing results (131-140 of 138) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 138 results.
International Journal of Clinical Oncology|July 13, 2022
Real-world efficacy and safety of nivolumab plus ipilimumab in untreated metastatic renal cell carcinoma, and the impact of previous nephrectomy on clinical outcome: Japanese multi-institutional retrospective studyTaigo Kato, Kazutoshi Fujita, Takafumi Minami, et al.
BJUI Compass|May 4, 2026
Preoperative FAN score predicts survival outcomes after radical cystectomy for bladder cancerYu Ishizuya, Atsunari Kawashima, Shimpei Yamashita, et al.
British Journal of Cancer|July 6, 2022
EphA2 on urinary extracellular vesicles as a novel biomarker for bladder cancer diagnosis and its effect on the invasiveness of bladder cancerEisuke Tomiyama, Kazutoshi Fujita, Kyosuke Matsuzaki, et al.
Cancer Science|December 4, 2024
Comparative analysis of gut microbiota in hormone-sensitive and castration-resistant prostate cancer in Japanese menSaizo Fujimoto, Koji Hatano, Eri Banno, et al.
International Journal of Clinical Oncology|September 2, 2024
Clinical outcomes of first-line combination therapy with immune checkpoint inhibitor for metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study in JapanAkihiro Yoshimura, Taigo Kato, Yasutomo Nakai, et al.
Cancer Treatment and Research Communications|May 29, 2026
Neutrophil-to-lymphocyte ratio and performance status are associated with increased risk of skin toxicity in patients receiving enfortumab vedotin with or without pembrolizumab for metastatic urothelial carcinomaYujiro Hayashi, Atsunari Kawashima, Yoshiyuki Yamamoto, et al.
The International Journal of Neuropsychopharmacology|December 17, 2008
A randomized cross-over study of a traditional Japanese medicine (kampo), yokukansan, in the treatment of the behavioural and psychological symptoms of dementiaKatsuyoshi Mizukami, Takashi Asada, Toru Kinoshita, et al.
Scientific Reports|December 12, 2025
Real-world efficacy and safety of pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: a multi-institutional retrospective studyTaigo Kato, Yasutomo Nakai, Mototaka Sato, et al.
Pageof 14

Showing results (131-140 of 138) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 138 results.
International Journal of Clinical Oncology|July 13, 2022
Real-world efficacy and safety of nivolumab plus ipilimumab in untreated metastatic renal cell carcinoma, and the impact of previous nephrectomy on clinical outcome: Japanese multi-institutional retrospective studyTaigo Kato, Kazutoshi Fujita, Takafumi Minami, et al.
BJUI Compass|May 4, 2026
Preoperative FAN score predicts survival outcomes after radical cystectomy for bladder cancerYu Ishizuya, Atsunari Kawashima, Shimpei Yamashita, et al.
British Journal of Cancer|July 6, 2022
EphA2 on urinary extracellular vesicles as a novel biomarker for bladder cancer diagnosis and its effect on the invasiveness of bladder cancerEisuke Tomiyama, Kazutoshi Fujita, Kyosuke Matsuzaki, et al.
Cancer Science|December 4, 2024
Comparative analysis of gut microbiota in hormone-sensitive and castration-resistant prostate cancer in Japanese menSaizo Fujimoto, Koji Hatano, Eri Banno, et al.
International Journal of Clinical Oncology|September 2, 2024
Clinical outcomes of first-line combination therapy with immune checkpoint inhibitor for metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study in JapanAkihiro Yoshimura, Taigo Kato, Yasutomo Nakai, et al.
Cancer Treatment and Research Communications|May 29, 2026
Neutrophil-to-lymphocyte ratio and performance status are associated with increased risk of skin toxicity in patients receiving enfortumab vedotin with or without pembrolizumab for metastatic urothelial carcinomaYujiro Hayashi, Atsunari Kawashima, Yoshiyuki Yamamoto, et al.
The International Journal of Neuropsychopharmacology|December 17, 2008
A randomized cross-over study of a traditional Japanese medicine (kampo), yokukansan, in the treatment of the behavioural and psychological symptoms of dementiaKatsuyoshi Mizukami, Takashi Asada, Toru Kinoshita, et al.
Scientific Reports|December 12, 2025
Real-world efficacy and safety of pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: a multi-institutional retrospective studyTaigo Kato, Yasutomo Nakai, Mototaka Sato, et al.
Pageof 14